DESIGN ACID DEVELOPMENT OF SEQUENCE SELECTIVE LEXITROPSIN DNA MINOR-GROOVE BINDERS

被引:34
作者
LOWN, JW
机构
[1] Department of Chemistry, University of Alberta, Edmonton, Alberta
关键词
CANCER; ANTIGENE; ANTICANCER; ANTIVIRAL; DNA MINOR GROOVE;
D O I
10.1002/ddr.430340207
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The concept of lexitropsins, or information-reading molecules, is introduced within the antigene strategy as an alternative to, and complementary with, the antisense approach for cellular intervention and gene control. Consideration is given to alternative approaches to the development of DNA sequence selective binding agents because of their potential applications in diagnosis and treatment of cancer as well as in molecular biology. The chemical, physical, and pharmacological factors involved in the design of effective lexitropsins are discussed and illustrated with experimental results. Among the factors contributing to the molecular recognition processes are: the presence and disposition of hydrogen bond accepting and donating groups, ligand shape, chirality, stereochemistry, flexibility, and charge. For longer ligands, such as are required to target unique sequences in biological systems (14-16 base pairs), the critical feature is the phasing or spatial correspondence between repeat units in the ligand and the receptor. The recently discovered 2:1 lexitropsin-DNA binding motif provides a further refinement in molecular recognition in permitting discrimination between CC and CG base pairs. The application of these factors in the design and synthesis of novel agents which exhibit anticancer, antiviral, and antiretroviral properties, and in the inhibition of critical cellular enzymes including topoisomerases, is discussed. The emerging evidence of a relationship between sequence selectivity of the new agents and the biological response they invoke is also described. (C) 1995 Wiley-Liss, Inc.
引用
收藏
页码:145 / 183
页数:39
相关论文
共 206 条
[1]   FTIR STUDY OF SPECIFIC BINDING INTERACTIONS BETWEEN DNA MINOR GROOVE BINDING LIGANDS AND POLYNUCLEOTIDES [J].
ADNET, F ;
LIQUIER, J ;
TAILLANDIER, E ;
SINGH, MP ;
RAO, KE ;
LOWN, JW .
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 1992, 10 (03) :565-575
[2]   STRUCTURE + SYNTHESIS OF DISTAMYCIN A [J].
ARCAMONE, F ;
NICOLELL.V ;
PENCO, S ;
OREZZI, P ;
PIRELLI, A .
NATURE, 1964, 203 (494) :1064-+
[3]  
ARCAMONE F, 1958, Patent No. 1027667
[4]  
Arcamone F, 1967, GAZZ CHIM ITAL, V97, P1097
[5]  
ARCAMONE F, 1972, MED CHEM, P29
[6]  
AUCLAIR C, 1990, JERUS SYM Q, V23, P247
[7]  
BAILLY C, 1992, MOL PHARMACOL, V41, P845
[8]   DESIGN, SYNTHESIS, DNA-BINDING, AND BIOLOGICAL-ACTIVITY OF A SERIES OF DNA MINOR-GROOVE-BINDING INTERCALATING DRUGS [J].
BAILLY, C ;
POMMERY, N ;
HOUSSIN, R ;
HENICHART, JP .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1989, 78 (11) :910-917
[9]   BINDING-PROPERTIES AND DNA SEQUENCE-SPECIFIC RECOGNITION OF 2 BITHIAZOLE-LINKED NETROPSIN HYBRID MOLECULES [J].
BAILLY, C ;
COLSON, P ;
HOUSSIER, C ;
HOUSSIN, R ;
MRANI, D ;
GOSSELIN, G ;
IMBACH, JL ;
WARING, MJ ;
LOWN, JW ;
HENICHART, JP .
BIOCHEMISTRY, 1992, 31 (35) :8349-8362
[10]   BIOLOGICAL-ACTIVITY AND MOLECULAR INTERACTION OF A NETROPSIN ACRIDINE HYBRID LIGAND WITH CHROMATIN AND TOPOISOMERASE II [J].
BAILLY, C ;
COLLYNDHOOGHE, M ;
LANTOINE, D ;
FOURNIER, C ;
HECQUET, B ;
FOSSE, P ;
SAUCIER, JM ;
COLSON, P ;
HOUSSIER, C ;
HENICHART, JP .
BIOCHEMICAL PHARMACOLOGY, 1992, 43 (03) :457-466